
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Patient Health Questionnaires
7-item General Anxiety Disorder Assessment
Major Depression Inventory
Hamilton Anxiety Scale
Geriatric Depression Assessment




